Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05597761 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 14, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 49
    • Site details revised at 3 of 3 sites
    v5
  2. Primary completion date: Sep 30, 2024 to Sep 30, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v4
  3. Primary endpoint revisedv3 Show 5 more changesShow less
    • Eligibility criteria shortened, about 44 words
    • Secondary endpoints: 9 to 4
    • Study description shortened, about 37 words
    • Site contacts updated at 1 of 3 sites
    • Study title shortened, about 3 words
  4. Lead sponsor: University of Cologne to Oliver Cornely, MDv2 Show 9 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 30, 2023 to Sep 30, 2024
    • Start date changed from estimate of Oct 31, 2022 to May 15, 2023
    • Primary endpoint revised
    • Study sites: 1 to 3
    • Eligibility criteria shortened, about 51 words
    • Secondary endpoints revised (9)
    • Study description expanded, about 4 words
    • Study title expanded, about 3 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.
Trial Details
NCT Number NCT05597761
Lead Sponsor Oliver Cornely, MD
Collaborators: ZKS Köln, German Federal Ministry of Education and Research
Conditions
(from sponsor)		 COVID-19, Adult, Immunocompromised Patients
Related terms COVID-19
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov